In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
19 authors at 2 institutions in 2 countries.
Kaloyan M TsanovCancer Biology & Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9007-4844 Francisco M BarrigaCancer Biology & Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-0996-7707 Yu-Jui HoCancer Biology & Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-7540-024X Direna Alonso-CurbeloCancer Biology & Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-6674-3059 Geulah LivshitsCancer Biology & Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-3835-7377 Richard P KocheCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-6820-5083 Timour BaslanCancer Biology & Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-5674-6432 Janelle SimonCancer Biology & Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sha TianCancer Biology & Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alexandra N WuestCancer Biology & Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-7337-8619 Wei LuanCancer Biology & Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
John E WilkinsonDepartment of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA.ORCID 0000-0001-9174-8556 Ignas MasilionisComputational & Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-7937-9014 Nevenka DimitrovaCancer Biology & Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4091-9233 Christine A Iacobuzio-DonahueDavid M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-4672-3023 Ronan ChalignéComputational & Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4332-3291 Dana Pe'erComputational & Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-9259-8817 Joan MassaguéCancer Biology & Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9324-8408 Scott W LoweCancer Biology & Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Memorial Sloan Kettering Cancer Center · USUniversity of Michigan · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MVIRAL TRANSACTIVATIONP01CA013106 · NCI · COLD SPRING HARBOR LABORATORY · PI William Richard McCombie · 1985 to 2026
$116.8MThe TGF Beta Signaling Pathway in Development and CancerR35CA252978 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JOAN MASSAGUE · 2020 to 2026
$7.3MTranslational Research in Oncology Training ProgramT32CA160001 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2011 to 2020
$2.0MElucidating determinants of metastasis suppression in pancreatic cancerK99CA266939 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI TSANOV, KALOYAN M. · 2022 to 2023
$271kMechanisms of tumor suppression by epigenetic regulators in pancreatic cancerF32CA177072 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LIVSHITS, GEULAH YEVGENIYA · 2013 to 2016
$168kNCI NIH HHS F32 CA177072NCI NIH HHS K99 CA266939NCI NIH HHS P01 CA013106NCI NIH HHS P30 CA008748NCI NIH HHS R35 CA252978NCI NIH HHS T32 CA160001
6 · The paper itselfAbstract
Driver gene mutations can increase the metastatic potential of the primary tumor
Identifiers
PMID38562717
PMCPMC10983983
OpenAlexW4392915056
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390